Cargando…

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Lipocalin 2 (LCN2) is a small secreted protein and its elevated expression has been observed in pancreatic as well as other cancer types. LCN2 has been reported to promote resistance to drug-induced apoptosis, enhance invasion through its physical association with matrix metalloproteinase-9, and pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Lisa, Radulovich, Nikolina, Zhu, Chang-Qi, Organ, Shawna, Bandarchi, Bizhan, Pintilie, Melania, To, Christine, Panchal, Devang, Tsao, Ming Sound
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464270/ https://www.ncbi.nlm.nih.gov/pubmed/23056397 http://dx.doi.org/10.1371/journal.pone.0046677

Ejemplares similares

Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma
por: Radulovich, Nikolina, et al.
Publicado: (2010)

p120RasGAP Is a Mediator of Rho Pathway Activation and Tumorigenicity in the DLD1 Colorectal Cancer Cell Line
por: Organ, Shawna L., et al.
Publicado: (2014)

Modified gateway system for double shRNA expression and Cre/lox based gene expression
por: Radulovich, Nikolina, et al.
Publicado: (2011)

Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor suppressive role in pancreatic ductal adenocarcinoma
por: Radulovich, Nikolina, et al.
Publicado: (2014)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
por: Siddiqui, Iram, et al.
Publicado: (2022)

Loss of Canonical Smad4 Signaling Promotes KRAS Driven Malignant Transformation of Human Pancreatic Duct Epithelial Cells and Metastasis
por: Leung, Lisa, et al.
Publicado: (2013)

Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts
por: Lohse, Ines, et al.
Publicado: (2014)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma
por: Vaz, Arokia Priyanka, et al.
Publicado: (2015)

Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma
por: Cole, Jennifer M., et al.
Publicado: (2019)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment
por: Jakubison, Brad L., et al.
Publicado: (2018)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
por: Rimmer, Ella, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
por: Zhu, Xiao‐Xu, et al.
Publicado: (2022)

Desmoglein 3 contributes to tumorigenicity of pancreatic ductal adenocarcinoma through activating Src–FAK signaling
por: Abula, Yimamumaimaitijiang, et al.
Publicado: (2021)

Snail-Overexpression Induces Epithelial-mesenchymal Transition and Metabolic Reprogramming in Human Pancreatic Ductal Adenocarcinoma and Non-tumorigenic Ductal Cells
por: Liu, Menghan, et al.
Publicado: (2019)

Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor
por: Derouet, Mathieu F., et al.
Publicado: (2020)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer
por: Hai, Josephine, et al.
Publicado: (2017)

A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas
por: Parameswaran, Neetha, et al.
Publicado: (2019)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model
por: Donohue, Elizabeth, et al.
Publicado: (2013)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach
por: Aier, Imlimaong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ne96g2kpi51fqvp1esfj37v47i